Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients.

Marc Foca Salih Demirhan Flor Muñoz Rivas Kristen G Valencia Deray Claire E Bocchini Tanvi S Sharma Gilad Sherman William J Muller Taylor Heald-Sargent Lara A Danziger-IsakovSamantha BlumJuri Boguniewicz Samantha BaconTuhina JosephJodi M Smith Monica I ArduraYin SuGayatri Shankar Chilambi Jose A Ferrolino Betsy C Herold

Published in: Open forum infectious diseases (2024)

CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.

Keyphrases

healthcare
oxidative stress
cross sectional
emergency department
clinical trial
adverse drug
case control
oxide nanoparticles
breast cancer risk